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Objectives: Electronic Patient Reported Outcomes (PRO) provide quick and reli-
able assessment of patients’ health-related quality of life (HRQL). An electronic 
version of the PROQOL-HIV questionnaire was developed, and its face validity 
and reliability were assessed using standard psychometric methods. MethOds: 
A total of 70 French outpatients (63% males, mean age 47 years) were recruited. 
Hard copy and electronic questionnaires were completed in a randomized cross-
over design (2-7 day interval). Biomedical data were collected. Questionnaire ver-
sion and order effects were tested on full scale scores in a two-way ANOVA with 
patients as random effects. Test-retest reliability was evaluated using Pearson and 
intra-class correlation coefficients (with 95% confidence interval) for each dimen-
sion. Usability testing was carried out from patients’ survey reports, specifically: 
general satisfaction, ease of completion, quality and clarity of user interface (UI) 
and self motivation for electronic measuring to monitor HRQL in clinical follow-
up. Results: Questionnaire version and administration order effects (N= 58 
complete cases) were not significant at the 5% level, nor interacting together 
(p= 0.940). Reliability indices were acceptable, with Pearson correlations above 
0.7 and intra-class correlations ranging from 0.696 to 0.926, and scores were not 
statistically different between the two versions. On 77% of complete surveys, 57% 
of patients reported being satisfied and interested in electronic assessment of 
their HRQL in clinical follow up. Individual ratings of PROQOL-HIV user interface 
(85-100% of positive responses) confirmed UI clarity and usability. cOnclusiOns: 
The electronic PROQOL-HIV introduces minor modifications compared to the 
original paper-based version, following ISPOR ePRO Task Force guidelines, and 
it showed good reliability and face validity. Patients can complete the computer-
ized PROQOL-HIV questionnaire as intended and scores delivered from paper or 
electronic version share comparable accuracy and interpretation.
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Objectives: The immunization is currently one of the most discussed topics in 
the population and the number of its opponents is increasing. MethOds: Opinion, 
awareness and knowledge of parents (n-parents= 240, n-children= 463) about child-
hood immunization through self-reported technique of a questionnaire survey was 
conducted, with respect of gender, age, education and profession of parents in 
regard of their professional connection with health care in case of obligatory and 
recommended childhood vaccination. Results: In case of obligatory childhood 
vaccination all evaluated parameters influence and change opinion, awareness 
and knowledge of parents. Age (p< 0,01, Degree of freedom (df)= 10, Chi-squared 
distribution (χ ²)= 81,08, table value of Chi-squared distribution (tχ ²)= 23,21); gender 
(p< 0,01, df= 2, χ ²= 12,87, tχ ²= 9,21); education (p< 0,01, df= 10, χ ²= 79,11, tχ ²= 23,21); 
health care profession (p< 0,01, df= 2, χ ²= 13,75, tχ ²= 9,21. In case of recommended 
childhood vaccination all analyzed parameters influence and change parents’ 
opinion, awareness and knowledge, except for those working in health care. Age 
(p< 0,01, df= 5, χ ²= 13,29, tχ ²= 15,09); gender (p< 0,01, df= , χ ²= 79,82, tχ ²= 13,28); educa-
tion (p< 0,01, df= 4, χ ²= 49,10, tχ ²= 13,28); health care profession (0,01< p< 0,03, df= 1, 
χ ²= 4,85, tχ ²= 6,64). cOnclusiOns: Analysis confirms that age, gender, education 
and profession connected with health care influence and change parents’ opinion, 
awareness and knowledge about obligatory childhood vaccination. Regarding the 
recommended childhood vaccination, age, gender and education influence and 
change parents’ opinion, awareness and knowledge, although a profession con-
nected with health care neither influences, nor changes opinion, awareness and 
knowledge of the parents.
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Objectives: Both chronic HCV infection and current treatments negatively impact 
patient reported outcomes. PegIFN/RBV-based therapies decrease general HRQoL 
scores 10%-30% (on SF-36). Psychometric analyses of validity, responsiveness, 
and MID for the HCV-specific HCV-PRO instrument were performed. MethOds: 
Responses to the HCV-PRO (presented ILC2012), the SF-36, and EuroQol-5D 
(EQ-5D)+VAS were analyzed in the M11-602 trial of pegIFN/RBV with placebo 
(n= 11) or DAA: ABT-450/ ritonavir (n= 24), ABT-072 (n= 23), or ABT-333 (n= 16). 
DAAs were administered for 12 weeks, pegIFN/RBV for 48 weeks. PRO instru-
ments were administered at baseline, week 8, end of DAA treatment (EODT), end 
of pegIFN/RBV treatment (EOT), and posttreatment week 24 (PT24). Convergent 
validity of HCV-PRO total score (range 0-100) was assessed through correlation 
(Pearson’s) to SF-36 MCS/PCS and EQ-5D VAS scores. Discriminant validity was 
assessed by dichotomizing HCV-PRO responses on EQ-5D Anxiety/Depression 
dimension severity (none vs. some) and treatment emergent depression/fatigue 
adverse events (MedDRA terms). Responsiveness was assessed through analyses 
of effect size (ES). MID was assessed by standard error of the mean (SEM) and 
The initial step involved undertaking a review of published literature detail-
ing HIV patients’ experiences of receiving ARV therapy. These findings formed 
the basis of a meeting of leading European HIV clinical experts, prominent HIV 
organisation representatives and patients themselves. Results: The literature 
revealed numerous factors such as convenience, tolerability, relationship with 
physician and disease characteristics which influences patients’ satisfaction 
with treatment. Discussion between the clinicians, representative from patient 
organisations emphasised the importance of patient preferences as they relate 
to adherence with HIV therapy. This additional insight emphasised the under-
recognised role played by individual differences and therapeutic knowledge 
in defining attitudes to treatments. cOnclusiOns: Treatment satisfaction is 
a complex issue. The work undertaken so far has highlighted that despite the 
advances in ARVs there are still concerns for PLWH. The next stage of research 
involves undertaking a series of in-depth qualitative interviews with patients 
across Europe and examining attributes of HIV treatment using the discrete 
choice experiment methodology.
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Objectives: To determine parental preferences concerning rotavirus vaccination 
for their newborn baby, and to calculate the potential vaccination coverage for dif-
ferent vaccine scenarios. MethOds: A Discrete Choice Experiment (DCE) question-
naire was sent to the parents of 1,250 newborns aged 6 weeks in The Netherlands. 
The DCE included nine D-efficient designed choice tasks. Panel-mixed-logit models 
were used to estimate the relative importance of the five included rotavirus vaccine 
attributes; vaccine effectiveness, frequency of severe side effects, protection dura-
tion, location of vaccine administration, out-of-pocket costs. The potential uptake 
or vaccine coverage was calculated for different vaccine scenarios. Results: All 
attributes showed a significant estimate (P< .05). Parents were more likely to get 
their newborn vaccinated if the vaccine effectiveness increased, parents preferred 
a frequency of 1 in 1,000,000 children that suffer from severe side effects over a 
frequency of 1 in 10,000. Protection duration of 3 years was preferred over 1 year 
and parents preferred to get their child vaccinated at the GP’s office. Finally, increas-
ing out-of-pocket costs were associated with decreased willingness to vaccinate. 
With respect to the relative importance of these attributes, vaccine effectiveness 
was most decisive for parents, followed by out-of-pocket costs, protection duration 
and frequency of severe side effects. Vaccination coverage rates ranged between 
22.8% for the least preferred vaccine scenario and 87.5% for the most preferred 
scenario. cOnclusiOns: When deciding whether to vaccinate their newborn baby 
against the rotavirus, parents are mostly driven by the effectiveness of the vaccine, 
the out-of-pocket costs, protection duration and the frequency of severe side effects. 
Differences in vaccine scenarios resulted in a large range in expected vaccination 
coverage. Therefore, the context and content of the implementation strategy of the 
vaccination is expected to strongly affect the vaccination coverage. Specifically 
requesting an out-of-pocket payment of parents should be considered carefully if 
a high vaccine coverage is desired.
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Objectives: To examine the value of adding simeprevir (SMV) to peginterferon 
and ribavirin (PR) for treatment of chronic hepatitis C virus infection using patient-
reported outcomes (PRO) and their concordance with virology endpoints and 
adverse events (AEs). MethOds: Patients rated severity of fatigue (FSS), depres-
sive symptoms (CES-D), and impairment in functioning (WPAI:HepC Productivity, 
Activity, Absenteeism) at baseline and throughout treatment/follow-up in three 
randomized, double-blind trials comparing addition of SMV or Placebo (PBO) dur-
ing initial 12 weeks of PR treatment. PR was administered for 48 weeks (PBO group) 
and either 24 or 48 weeks (SMV group) (response-guided therapy [RGT]). Analysis 
of pooled data from the trials using a piecewise-linear mixed model compared 
the area-under-the-curve from baseline to Wk60 (AUC60) between SMV/PR and 
PBO/PR for each PRO score. Subgroup analyses evaluated impact of Sustained 
Virologic Response 12 weeks post-treatment (SVR12), fibrosis level, and RGT on 
PRO scores. Results: Of 1178 patients studied, analyses included 768 SMV/PR- and 
393 PBO/PR-treated patients. 87.5% of the SMV/PR group met RGT and completed 
treatment in 24 weeks. Fatigue and anaemia AEs were comparable in both groups but 
FSS scores show clinically important increases in fatigue, lasting 6.9 weeks longer 
with PBO/PR (p < 0.001). No significant differences were observed for Absenteeism. 
Mean scores for all other PRO endpoints worsened from baseline to Wk4 in both 
groups and remained impaired to Wk24 (SMV/PR) and Wk48 (PBO/PR), resulting 
in significantly lower AUC60and fewer weeks with clinically important worsening 
scores with SMV/PR. PRO scores indicated better outcomes for patients who met RGT 
criteria or achieved SVR12; differences in PRO scores associated with fibrosis level 
were only observed in the PBO/PR group. cOnclusiOns: Greater efficacy of SMV/
PR enabled reduced treatment duration and less time with PR-related side effects 
without adding to the severity of side-effects during treatment.
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Objectives: Trials comparing addition of simeprevir (SMV) or placebo to peginter-
feron/ribavirin for treatment of chronic hepatitis C virus (HCV) infection found that 
all patient-reported outcome (PRO) measures except Absenteeism scores from the 
Work Productivity and Activity Impairment questionnaire for Hepatitis C (WPAI:HepC) 
showed similar patterns over time and significantly better outcomes for the SMV groups. 
Absenteeism scores using recommended scoring were available only if a patient was 
in the workforce at baseline and subsequent study visits. To appreciate movement into 
and/or out of the workforce in HCV trials, we propose two alternative scores for the 
WPAI:HepC: Missed Work and Work Impairment. MethOds: A total of 711 subjects com-
pleted the WPAI:HepC in the QUEST1 and QUEST2 SMV trials during study visits at base-
line and throughout treatment and follow-up. The WPAI:HepC assesses whether subjects 
were in the workforce during the past 7 days; and if so, number of hours missed from 
work due to HCV or its treatment/number of hours scheduled to work (Absenteeism); 
and how much productivity was impaired when working (Productivity Impairment). 
Revised scoring produced Missed Work scores (% hours not working in past week) and 
Work Impairment (Missed Work x Productivity Impairment) for all subjects at each study 
visit by setting scores for subjects not in the workforce to 100 (range 0 to 100% Missed 
Work or Work Impairment). Results: WPAI Missed Work score results showed modest 
differences between treatments but Work Impairment scores were significantly better 
for the SMV group with a pattern over time consistent with other PRO endpoints in the 
trials (p= 0.034). cOnclusiOns: Methods for evaluating impact of HCV treatment on 
work life in clinical trials need to provide data for all subjects in order to capture work 
force participation and productivity when working. Revised scoring of the WPAI:HepC 
enable more accurate comparison of treatment in clinical trials.
INfectIoN – Health care use & Policy studies
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Objectives: It is well recognized that HPV infection causes a substantial burden 
in females. The infection also causes a substantial burden in males as it is associ-
ated with HPV-related cancers. Traditional economic evaluations focus only on 
quantifying cost-effectiveness, however, it is increasingly recognized that immuni-
zations may generate broader benefits not captured in cost-effectiveness analysis. 
This research aimed at developing a government-perspective health investment 
model to estimate the fiscal impact of immunizing males and females with the 
quadrivalent HPV vaccine in Germany. MethOds: Methodologies from genera-
tional accounting, human capital and health economics were combined to esti-
mate the fiscal benefits of HPV immunization. Cohort models were developed 
simulating the medical costs and average lifetime fiscal transfers between the 
government and cohorts of 13-year-old immunized and non-immunized indi-
viduals. To estimate tax revenue attributed to immunization-related changes in 
morbidity and mortality, direct and indirect tax rates were linked to differences 
in age- and gender-specific earnings. Results: The lifetime discounted gross tax 
for the immunized male and female cohorts (n= 400,000 each) were € 208.7 billion 
and € 130.4 billion, respectively. Over the lifetime of the female and male birth-
cohorts, it was estimated that immunization with the quadrivalent HPV vaccine 
would result in the prevention of 986 female and 296 male HPV-related deaths. 
Compared to the non-immunized cohorts of 13-year old males and females, the 
immunized cohorts resulted in higher total net discounted tax by € 106.1 million 
and higher total gross discounted tax by € 80.4 million. cOnclusiOns: The com-
bined vaccination of males and females in Germany results in positive lifetime net 
and gross discounted tax revenues for the government. The vaccination of males 
and females with the quadrivalent HPV vaccine is likely to have positive effects 
on public finances and economic growth over subsequent generations.
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Objectives: To date, efforts to model Clostridium difficile infection (CDI) have 
been limited. Most models do not address the contribution of asymptomatic carri-
ers as sources of new infections and are restricted to hospital acquired CDI. We aim 
to develop a simulation model to systematically examine the dynamic relationship 
between three major subpopulations of CDI transmission: hospitals, communities, 
and long-term facilities, to evaluate treatment effectiveness and costs. MethOds: 
We conducted a systematic investigation to determine the key epidemiological 
factors influencing CDI transmission according to the three major subpopula-
tions: hospitals, communities, and long-term care facilities. We have developed a 
stochastic agent-tracking meta-population network model of CDI transmission, 
and identified parameters that would capture transmission from symptomatic 
and asymptomatic carriers to uninfected individuals among the subpopula-
tions. Results: We identified eight infection states: susceptible, gastrointestinal 
exposure, colonized, diseased, deceased, clinically resolved colonized, relapse of 
CDI, and cleared. Key parameters include; health outcomes of target populations, 
time horizon, diagnostic characteristics, treatment effectiveness, transmission 
rates, susceptibility rates, recurrence rates, and costs. Initial treatments of CDI 
do not induce a lasting response in 15%-25% of patients. The estimated effective-
ness of antibiotic therapy for a first recurrence is 60% and declining with multiple 
recurrences. Major predictors of recurrences were advanced age and duration of 
initial hospitalizations. Recurrences of CDI were associated with major increases 
in hospital LOS and costs. cOnclusiOns: Our dynamic network model of CDI 
transmission will improve the capacity to project and to quantify the impact of a 
CDI outbreak in terms of clinical burden and costs.
Receiver Operating Characteristics (ROC) curves correlating HCV-PRO score to MID 
anchors on SF–36 MCS/PCS and EQ-5D VAS. Results: Demographics (N= 74): 22% 
female, 81% white, 51% > 50 years of age, 74% Genotype 1a, 69% IL28B non-CC 
status. Convergent validity: HCV-PRO total score correlations with SF-36 MCS/
PCS and EQ-5D VAS scores were 0.64-0.93 (all time points). Discriminant valid-
ity: HCV-PRO scores decreased 10-30 points more in subjects impaired by anxi-
ety/depression (EQ-5D) or experiencing depression/fatigue events. ES showed an 
increasing impact during treatment (-0.66, week 8; -0.76, EODT; –0.93, EOT). At 
PT24, ES returned to -0.10. SEM and ROC analyses suggested an HCV-PRO MID 
approximating -10 points. cOnclusiOns: The HCV-PRO is a valid, responsive, 
disease-specific instrument. In this study, an MID of approximately -10 points 
was identified. The HCV-PRO may enhance understanding of how HCV treatment 
impacts function/wellbeing.
PIN124
aN assessmeNt of uNemPloymeNt amoNg PeoPle lIVINg wItH HIV/aIds 
IN caNada aNd euroPe
Cline S.K1, Wang S.1, Van Wyk J.2, Baran R.W.1, Gooch K.L.1
1AbbVie, North Chicago, IL, USA, 2AbbVie, Maidenhead, UK
Objectives: Neurocognitive impairment (NCI), depression, and duration of unem-
ployment have been reported as barriers to obtaining employment among people liv-
ing with HIV/AIDS (PLWHA) in the US. However, upon return to work, improvements in 
depression and health-related quality of life (HRQoL) have been observed. The objec-
tives of this study were to examine the burden of unemployment among PLWHA in 
Canada and Europe by 1.) estimating the number of PLWHA who are unemployed and 
their duration of unemployment, and (2) determining patient characteristics associ-
ated with being unemployed, including NCI, depression, and HRQoL. MethOds: Data 
was derived from CRANIum (sCReen for Anxiety, depression, and Neurocognitive 
Impairment in HIV+ patients), a multicenter, cross-sectional study of PLWHA in 14 
European countries and Canada between 2010 and 2011. Depression was assessed 
using the Hospital Anxiety and Depression Scale. NCI was assessed using the Brief 
Neurocognitive Screen, which consists of the Digit Symbol (DS) test and Trail Making 
tests A and B. HRQoL was assessed using the Medical Outcomes Study HIV Health 
Survey (MOS-HIV). Logistic regression was utilized in order to determine if these 
variables, in addition to demographic and clinical variables, were associated with 
unemployment. Results: A total of 2754 PLWHA (mean age = 43; 62% male) were 
included in these analyses; 960 (35%) were unemployed. Regarding the unemployed, 
110 (11%) had been unemployed for < 6 months, 99 (10%) for 6 to 12 months, and 737 
(77%) for > 12 months. Logistic regression analyses indicated that NCI, lower scores on 
the MOS-HIV physical health subscale, previous psychiatric diagnoses, lesser educa-
tion, Hepatitis B and/or C co-infection, older age and female gender were indepen-
dently associated with unemployment. Current depression was not associated with 
unemployment. cOnclusiOns: In tandem with previous reports, results from this 
multinational study suggest that NCI and HRQoL are salient issues with regards to 
employment among PLWHA internationally.
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Objectives: Chronic HCV infection and interferon-based treatments negatively 
impact PROs. The HCV-PRO is a validated disease-specific PRO instrument for patients 
with HCV. The purpose of this analysis was to ascertain the psychometric properties of 
the German-translated HCV-PRO. MethOds: Responses from German subjects to the 
HCV-PRO, SF-36v.2, and EQ-5D 5L+VAS were analyzed from the multinational AVIATOR 
trial of interferon-free oral DAA therapy in Genotype 1 patients. HCV-PRO was trans-
lated under Harmonization standards. Approved German-language validated ver-
sions of the SF-36 and EQ-5D were included for psychometric comparison. Internal 
consistency/reliability of HCV-PRO items and total score (range 0–100) were evaluated 
using Chronbach’s alpha. Convergent validity of HCV-PRO total score was assessed 
through Pearson’s correlation to SF-36 MCS/PCS and EQ-5D VAS scores (0.5–0.9 = 
moderate–strong). Discriminant validity was assessed by dichotomizing HCV-PRO 
total score on EQ-5D Anxiety/Depression and Pain/Discomfort dimensions by severity 
(none vs. some). Response range of HCV-PRO total score was examined. Analyses were 
performed at Baseline, week 8 (Wk8), End of Treatment (EOT), and 24 week follow-up 
(PTW24). Results: Demographics (N= 39): 46% female, 97% white, 46% ≥ 50 years 
of age, 36% Genotype 1a, 87% IL28B non-CC status. Clinical response was 92.3% of 
German patients achieving SVR24. Mean HCV-PRO, SF-36 MCS/PCS, and EQ-5D VAS 
scores were minimally changed during treatment (Wk8, EOT). Cronbach’s alpha for 
HCV-PRO items and total scores over time were 0.92–0.96. HCV-PRO total score exhib-
ited moderate-to-high correlation with SF-36 MCS/PCS and EQ-5D VAS total scores 
at each time period (r= 0.42–0.85), with highest correlation with SF-36 MCS. HCV-PRO 
mean scores were lower in subjects with anxiety/depression or pain/discomfort vs. 
none (p< 0.01). Mean HCV-PRO score at PTW24 was improved (p= 0.038) over baseline. 
Baseline HCV-PRO floor (0%) and ceiling (10%) scores were acceptable. cOnclusiOns: 
The German-translated HCV-PRO is a valid, responsive, disease-specific instrument 
for German-speaking HCV-infected people.
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